Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis

Emerging Infectious Diseases
Muhammad OsmanCollaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR TB

Abstract

Extensively drug-resistant tuberculosis (XDR TB) has extremely poor treatment outcomes in adults. Limited data are available for children. We report on clinical manifestations, treatment, and outcomes for 37 children (<15 years of age) with bacteriologically confirmed XDR TB in 11 countries. These patients were managed during 1999-2013. For the 37 children, median age was 11 years, 32 (87%) had pulmonary TB, and 29 had a recorded HIV status; 7 (24%) were infected with HIV. Median treatment duration was 7.0 months for the intensive phase and 12.2 months for the continuation phase. Thirty (81%) children had favorable treatment outcomes. Four (11%) died, 1 (3%) failed treatment, and 2 (5%) did not complete treatment. We found a high proportion of favorable treatment outcomes among children, with mortality rates markedly lower than for adults. Regimens and duration of treatment varied considerably. Evaluation of new regimens in children is required.

References

Jun 3, 2006·Pediatrics·Peter C DrobacMercedes C Becerra
Jul 12, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ritu BanerjeeJennifer Flood
Nov 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James A SeddonH Simon Schaaf
Jan 13, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·N R GandhiN S Shah
Feb 9, 2012·The Pediatric Infectious Disease Journal·Catherine A WisemanAnneke C Hesseling
Jun 16, 2012·The European Respiratory Journal·James A SeddonH Simon Schaaf
Jul 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Heather J ZarMark P Nicol
Sep 7, 2012·PLoS Medicine·Shama D AhujaUNKNOWN Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB
Sep 11, 2012·The Journal of Infection·James A SeddonH Simon Schaaf
Oct 13, 2012·The European Respiratory Journal·G B MiglioriUNKNOWN “The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB”
Oct 27, 2012·The European Respiratory Journal·Dennis FalzonUNKNOWN Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB
Apr 12, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·M GegiaJ Furin
Jun 8, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Z ZhangY Zhao
Aug 12, 2014·The Lancet Infectious Diseases·Silvia S ChiangMercedes C Becerra
Sep 6, 2014·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·R M HicksM R O'Donnell
May 7, 2015·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·B K MooreH Menzies
Feb 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Olivier MarcyChristophe Delacourt
Feb 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anne K Detjen, Elisabetta Walters
Mar 13, 2016·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A SwaminathanJ Achar
Jun 28, 2016·The Lancet Infectious Diseases·Peter J DoddJames A Seddon
Nov 2, 2016·The European Respiratory Journal·Polina A SmirnovaAndrey O Maryandyshev
Aug 2, 2017·Emerging Infectious Diseases·Jay AcharPhilipp du Cros
Aug 16, 2017·The Lancet Global Health·Peter J DoddHelen E Jenkins
Jul 12, 2018·PLoS Medicine·Elizabeth P HarauszUNKNOWN Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB

❮ Previous
Next ❯

Citations

Aug 10, 2019·The Pediatric Infectious Disease Journal·Elena ChiappiniLuisa Galli
May 7, 2020·Current Opinion in Pediatrics·Annaleise R Howard-Jones, Ben J Marais
Feb 28, 2020·Indian Journal of Pediatrics·Ira ShahHimali Meshram
Jan 20, 2021·The Pediatric Infectious Disease Journal·Haude CogoVirginie Pommelet
Sep 6, 2019·The Lancet. Respiratory Medicine·Keertan DhedaUNKNOWN Lancet Respiratory Medicine drug-resistant tuberculosis Commission group

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Current Opinion in Infectious Diseases
Philip LoBue
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
H Cox, N Ford
American Journal of Respiratory and Critical Care Medicine
Neel R GandhiTugela Ferry Care and Research (TF CARES) Collaboration
© 2022 Meta ULC. All rights reserved